Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | TSC2 |
Variant | E96* |
Impact List | nonsense |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | TSC2 E96* results in a premature truncation of the Tsc2 protein at amino acid 96 of 1807 (UniProt.org). E96* has not been characterized however, due to the effects of other truncation mutations downstream of E96 (PMID: 22903760, PMID: 31454656), is predicted to lead to a loss of Tsc2 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
TSC2 mutant TSC2 inact mut TSC2 E96* |
Transcript | NM_000548.5 |
gDNA | chr16:g.2053402G>T |
cDNA | c.286G>T |
Protein | p.E96* |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_024450413.1 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_001406673.1 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
XM_005255529 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_001406690.1 | chr16:g.2065549G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
XM_011522637 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_001406692.1 | chr16:g.2065549G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
XM_011522636.2 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
XM_011522636 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_001406695.1 | chr16:g.2065549G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_001406693.1 | chr16:g.2065549G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_001406663.1 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
XM_017023618.1 | chr16:g.2065549G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
XM_017023618 | chr16:g.2065549G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
XM_011522640.2 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_001370405.1 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_000548 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_001406697.1 | chr16:g.2065549G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_001077183.2 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_001406667.1 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_001114382 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
XM_011522639 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_001406671.1 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_000548.4 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_001406696.1 | chr16:g.2065549G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_001406664.1 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
XM_011522637.3 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
XM_017023615 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_001114382.2 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
XM_011522640 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
XM_011522639.2 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
XM_005255529.4 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_021055.3 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_001406691.1 | chr16:g.2065549G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_001406689.1 | chr16:g.2065549G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_001406665.1 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_001370404.1 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
XM_017023616.1 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_001406668.1 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
XM_005255531.4 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
XM_017023615.1 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_001406694.1 | chr16:g.2065549G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
XM_011522637.2 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_001077183.3 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
XM_005255531 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
XM_011522636.3 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_000548.5 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_001114382.3 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_001363528.2 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
XM_011522639.3 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
NM_001077183 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
XM_017023616 | chr16:g.2053402G>T | c.286G>T | p.E96* | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TSC2 E96* | hepatocellular carcinoma | predicted - sensitive | Everolimus | Case Reports/Case Series | Actionable | In a clinical study, a hepatocellular carcinoma patient harboring TSC2 E96* achieved stable disease following treatment with Afinitor (everolimus) (PMID: 30373752). | 30373752 |